Free Trial

MiNK Therapeutics (INKT) Stock Price, News & Analysis

MiNK Therapeutics logo
$14.16 +0.11 (+0.78%)
Closing price 10/23/2025 04:00 PM Eastern
Extended Trading
$14.14 -0.02 (-0.14%)
As of 10/23/2025 07:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About MiNK Therapeutics Stock (NASDAQ:INKT)

Advanced

Key Stats

Today's Range
$14.05
$14.51
50-Day Range
$13.61
$16.30
52-Week Range
$4.56
$76.00
Volume
9,411 shs
Average Volume
32,954 shs
Market Capitalization
$64.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$37.50
Consensus Rating
Moderate Buy

Company Overview

MiNK Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
55th Percentile Overall Score

INKT MarketRank™: 

MiNK Therapeutics scored higher than 55% of companies evaluated by MarketBeat, and ranked 486th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    MiNK Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and 1 sell rating.

  • Upside Potential

    MiNK Therapeutics has a consensus price target of $37.50, representing about 164.8% upside from its current price of $14.16.

  • Amount of Analyst Coverage

    MiNK Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about MiNK Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for MiNK Therapeutics are expected to grow in the coming year, from ($2.75) to ($2.45) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of MiNK Therapeutics is -4.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of MiNK Therapeutics is -4.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about MiNK Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    6.42% of the float of MiNK Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    MiNK Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in MiNK Therapeutics has recently increased by 41.14%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    MiNK Therapeutics does not currently pay a dividend.

  • Dividend Growth

    MiNK Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.42% of the float of MiNK Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    MiNK Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in MiNK Therapeutics has recently increased by 41.14%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    MiNK Therapeutics has a news sentiment score of 1.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for MiNK Therapeutics this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    3 people have added MiNK Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, MiNK Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    22.48% of the stock of MiNK Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 2.87% of the stock of MiNK Therapeutics is held by institutions.

  • Read more about MiNK Therapeutics' insider trading history.
Receive INKT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MiNK Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

INKT Stock News Headlines

It’s Time to Buy “the NVIDIA of Quantum Computing”
Yahoo Finance wrote that investing in quantum computing could... "Lead to life-changing returns... and make you the millionaire next door." But why are quantum computers so revolutionary? Could it really be bigger than AI?tc pixel
See More Headlines

INKT Stock Analysis - Frequently Asked Questions

MiNK Therapeutics' stock was trading at $6.9690 at the beginning of 2025. Since then, INKT shares have increased by 103.2% and is now trading at $14.16.

MiNK Therapeutics, Inc. (NASDAQ:INKT) announced its earnings results on Thursday, August, 14th. The company reported ($1.06) earnings per share for the quarter, missing analysts' consensus estimates of ($0.55) by $0.51.
Read the conference call transcript
.

MiNK Therapeutics's stock reverse split on Tuesday, January 28th 2025.The 1-10 reverse split was announced on Tuesday, January 21st 2025. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

MiNK Therapeutics (INKT) raised $43 million in an IPO on Friday, October 15th 2021. The company issued 3,333,334 shares at a price of $12.00-$14.00 per share.

Shares of INKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that MiNK Therapeutics investors own include Agenus (AGEN), HubSpot (HUBS), Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA) and Bank of America (BAC).

Company Calendar

Last Earnings
8/14/2025
Today
10/24/2025
Next Earnings (Estimated)
11/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:INKT
CIK
1840229
Fax
N/A
Employees
30
Year Founded
2017

Price Target and Rating

High Price Target
$40.00
Low Price Target
$35.00
Potential Upside/Downside
+164.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.88)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$9.51 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-227.24%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.15
Quick Ratio
0.15

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($4.94) per share
Price / Book
-2.87

Miscellaneous

Outstanding Shares
4,523,000
Free Float
3,506,000
Market Cap
$64.05 million
Optionable
No Data
Beta
0.33

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:INKT) was last updated on 10/24/2025 by MarketBeat.com Staff
From Our Partners